ATE304354T1 - Kaliumkanal-modulierende imidazolderivate - Google Patents

Kaliumkanal-modulierende imidazolderivate

Info

Publication number
ATE304354T1
ATE304354T1 AT02745529T AT02745529T ATE304354T1 AT E304354 T1 ATE304354 T1 AT E304354T1 AT 02745529 T AT02745529 T AT 02745529T AT 02745529 T AT02745529 T AT 02745529T AT E304354 T1 ATE304354 T1 AT E304354T1
Authority
AT
Austria
Prior art keywords
potassium channel
imidazole derivatives
channel modulating
disorders
neurodegenerating
Prior art date
Application number
AT02745529T
Other languages
English (en)
Inventor
Dennis Bigg
Jacques Pommier
Anne-Marie Liberatore
Original Assignee
Sod Conseils Rech Applic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sod Conseils Rech Applic filed Critical Sod Conseils Rech Applic
Application granted granted Critical
Publication of ATE304354T1 publication Critical patent/ATE304354T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Networks Using Active Elements (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Detergent Compositions (AREA)
  • Control Of Transmission Device (AREA)
  • Molds, Cores, And Manufacturing Methods Thereof (AREA)
AT02745529T 2001-06-14 2002-06-14 Kaliumkanal-modulierende imidazolderivate ATE304354T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0107820A FR2825926A1 (fr) 2001-06-14 2001-06-14 Derives d'imidazoles modulant les canaux sodiques
PCT/FR2002/002039 WO2002102375A2 (fr) 2001-06-14 2002-06-14 Derives d'imidazoles modulant les canaux sodiques

Publications (1)

Publication Number Publication Date
ATE304354T1 true ATE304354T1 (de) 2005-09-15

Family

ID=8864329

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02745529T ATE304354T1 (de) 2001-06-14 2002-06-14 Kaliumkanal-modulierende imidazolderivate

Country Status (21)

Country Link
US (3) US7157483B2 (de)
EP (1) EP1401432B1 (de)
JP (1) JP2005500297A (de)
KR (1) KR20040030672A (de)
CN (1) CN1535148A (de)
AT (1) ATE304354T1 (de)
BR (1) BR0210285A (de)
CA (1) CA2449916A1 (de)
CZ (1) CZ297321B6 (de)
DE (1) DE60206171T2 (de)
DK (1) DK1401432T3 (de)
ES (1) ES2249595T3 (de)
FR (1) FR2825926A1 (de)
HU (1) HUP0400195A3 (de)
IS (1) IS2367B (de)
MX (1) MXPA03011508A (de)
NO (1) NO20035553D0 (de)
NZ (1) NZ529741A (de)
PL (1) PL366722A1 (de)
RU (1) RU2296565C2 (de)
WO (1) WO2002102375A2 (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004210711B2 (en) * 2003-02-12 2010-07-08 Transtech Pharma, Inc. Substituted azole derivatives as therapeutic agents
ZA200507752B (en) * 2003-03-28 2007-01-31 Threshold Pharmaceuticals Inc Compositions and methods for treating cancer
AU2004293013B2 (en) * 2003-11-19 2011-04-28 Metabasis Therapeutics, Inc. Novel phosphorus-containing thyromimetics
CA2606499C (en) 2005-05-26 2017-06-13 Metabasis Therapeutics, Inc. Thyromimetics for the treatment of fatty liver diseases
AU2006263433B8 (en) 2005-06-29 2011-06-09 Immunogenesis, Inc. Phosphoramidate alkylator prodrugs
US20090291904A1 (en) * 2005-12-07 2009-11-26 Yoel Kashman Chemical derivatives of jasmonate, pharmaceutical compositions and methods of use thereof
CA2630666A1 (en) * 2005-12-07 2007-06-14 Sepal Pharma Ltd. Jasmonate derivatives, pharmaceutical compositions and methods of use thereof
US9284274B2 (en) 2005-12-07 2016-03-15 Ramot At Tel-Aviv University Ltd. Chemical derivatives of jasmonate, pharmaceutical compositions and methods of use thereof
WO2008083101A1 (en) 2006-12-26 2008-07-10 Threshold Pharmaceuticals, Inc. Phosphoramidate alkylator prodrugs for the treatment of cancer
US7883898B2 (en) * 2007-05-07 2011-02-08 General Electric Company Method and apparatus for measuring pH of low alkalinity solutions
US8188080B2 (en) * 2007-10-17 2012-05-29 Sanford-Burnham Medical Research Institute VHR protein tyrosine phosphatase inhibitors, compositions and methods of use
CN102046240B (zh) 2008-03-25 2014-06-25 阿费克蒂斯药品公司 新的p2x7r拮抗剂及其应用
US8815892B2 (en) 2008-03-25 2014-08-26 Affectis Pharmaceuticals Ag P2X7R antagonists and their use
MY158622A (en) * 2008-10-06 2016-10-31 Shikoku Chem 2-benzyl-4-(2,4-dichlorophenyl)-5-methylimidazole compound
US9284252B2 (en) 2009-06-09 2016-03-15 Sepal Pharma Ltd. Use of jasmonate ester derivatives for treating benign hyperproliferative skin disorders
JP5368244B2 (ja) * 2009-10-14 2013-12-18 四国化成工業株式会社 ２−（２，４−ジクロロベンジル）−４−アリール−５−メチルイミダゾール化合物
JP5368263B2 (ja) * 2009-11-04 2013-12-18 四国化成工業株式会社 ４−（２，４−ジクロロフェニル）−５−メチルイミダゾール化合物
JP5368271B2 (ja) * 2009-11-20 2013-12-18 四国化成工業株式会社 ４−（４−ビフェニリル）−２−（２，４−ジクロロベンジル）イミダゾールおよび表面処理液
BR112019010249A2 (pt) 2016-11-21 2019-09-10 Viking Therapeutics Inc método de tratamento de doença de armazenamento de glicogênio
US11707472B2 (en) 2017-06-05 2023-07-25 Viking Therapeutics, Inc. Compositions for the treatment of fibrosis
KR20200138283A (ko) 2018-03-22 2020-12-09 바이킹 테라퓨틱스 인코포레이티드 결정질 형태, 및 결정질 형태의 화합물을 제조하는 방법
US12102646B2 (en) 2018-12-05 2024-10-01 Viking Therapeutics, Inc. Compositions for the treatment of fibrosis and inflammation
WO2024097171A1 (en) * 2022-10-31 2024-05-10 Genep Inc. Imidazole compounds and their use as sodium channel inhibitors
WO2025231324A1 (en) * 2024-05-02 2025-11-06 Genep Inc. Imidazole compounds and their use as sodium channel inhibitors

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1046248A (en) * 1962-08-02 1966-10-19 Benger Lab Ltd Substituted imidazoles
AU518569B2 (en) * 1979-08-07 1981-10-08 Farmos-Yhtyma Oy 4-benzyl- and 4-benzoyl imidazole derivatives
EP0786455B1 (de) * 1994-09-26 2003-12-03 Shionogi & Co., Ltd. Imidazolderivat
PT1036065E (pt) * 1997-12-04 2004-09-30 Allergan Inc Derivados de imidazol substituidos com actividade do tipo agonista nos receptores alfa 2b ou 2b/2c adrenergicos
US6003118A (en) * 1997-12-16 1999-12-14 Acer Laboratories Inc. Method and apparatus for synchronizing clock distribution of a data processing system
JP4832647B2 (ja) * 1999-03-26 2011-12-07 ユーロ−セルティック エス． ア． アリール置換ピラゾール、イミダゾール、オキサゾール、チアゾールおよびピロール、ならびにそれらの使用
AR024077A1 (es) * 1999-05-25 2002-09-04 Smithkline Beecham Corp Compuestos antibacterianos
TWI283577B (en) * 1999-10-11 2007-07-11 Sod Conseils Rech Applic Pharmaceutical composition of imidazole derivatives acting as modulators of sodium channels and the use thereof
AU2261401A (en) * 1999-12-16 2001-06-25 Schering Corporation Substituted imidazole neuropeptide y y5 receptor antagonists

Also Published As

Publication number Publication date
US7157483B2 (en) 2007-01-02
FR2825926A1 (fr) 2002-12-20
EP1401432B1 (de) 2005-09-14
CN1535148A (zh) 2004-10-06
NO20035553D0 (no) 2003-12-12
IS7067A (is) 2003-12-08
EP1401432A2 (de) 2004-03-31
KR20040030672A (ko) 2004-04-09
IS2367B (is) 2008-06-15
RU2004100843A (ru) 2005-04-10
DE60206171D1 (de) 2005-10-20
CZ297321B6 (cs) 2006-11-15
HUP0400195A3 (en) 2004-10-28
CZ20033550A3 (cs) 2005-05-18
WO2002102375A2 (fr) 2002-12-27
DK1401432T3 (da) 2006-02-06
DE60206171T2 (de) 2006-06-22
RU2296565C2 (ru) 2007-04-10
JP2005500297A (ja) 2005-01-06
CA2449916A1 (fr) 2002-12-27
NZ529741A (en) 2006-10-27
MXPA03011508A (es) 2004-03-18
US20040198792A1 (en) 2004-10-07
BR0210285A (pt) 2004-06-29
US7402602B2 (en) 2008-07-22
US20070099975A1 (en) 2007-05-03
US20060069146A1 (en) 2006-03-30
WO2002102375A3 (fr) 2003-09-25
HUP0400195A2 (hu) 2004-07-28
PL366722A1 (en) 2005-02-07
ES2249595T3 (es) 2006-04-01

Similar Documents

Publication Publication Date Title
ATE304354T1 (de) Kaliumkanal-modulierende imidazolderivate
NO20021358L (no) Alkylendiamin-substituerte heterocykler
MXPA05007513A (es) Compuestos, composiciones y metodos.
EA200300829A1 (ru) Производные 1-арил- или 1-алкилсульфонилбензазола в качестве лигандов 5-гидрокситриптамина-6
MY140767A (en) Compounds, methods and compositions
SE0401971D0 (sv) Piperidne derivatives
ATE525067T1 (de) Amino-substituierte (e)-2,6-dialkoxystyryl 4- substituierte benzylsulfone zur behandlung von proliferierenden erkrankungen
DE60334536D1 (de) Furylverbindungen
ATE233274T1 (de) Oxyiminopregnancarbolactone
TW200500339A (en) Pyrrolidine derivatives, and process for the preparation
DE60045508D1 (de) Dalda-analoge und ihre verwendung
DK1483251T3 (da) C3-cyano-epothilon-derivater
DK1594885T3 (da) Lægemiddel til vækstinhibering af tumorer
MXPA05013905A (es) Compuestos de quinazolinona sustituidos por arilamina.
ATE549024T1 (de) Chinazolin-kaliumkanalhemmer
SE0203303D0 (sv) Novel Compounds
DE60311887D1 (de) Multifunktionelle kationische photoinitiatoren, deren herstellung und verwendung
TR200302288T2 (tr) Terapi için yeni bileşikler ve metotlar.
SE0203300D0 (sv) Novel Compounds
NZ552328A (en) Arylsulphonylstilbene derivatives for treatment of insomnia and related conditions
MXPA05006957A (es) Nuevos derivados de fosforamida.
ATE276259T1 (de) Dihydroporphyrinderivate und ihre verwendung
EA200400876A1 (ru) Способ получения производных толуола
TW200510312A (en) Diarylmethylidene piperidine derivatives, preparations thereof and uses thereof
SE0203301D0 (sv) Novel Compounds

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1401432

Country of ref document: EP

REN Ceased due to non-payment of the annual fee